Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YES1-stabilized CAR-NK
- Development stage
- Preclinical
- Lead developer
- Shandong University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
YES1-stabilized CAR-NK is an experimental chimeric antigen receptor natural killer (CAR-NK) cell therapy platform engineered to incorporate YES1 stabilization. Developed by researchers at Tongji University, Shandong University, and Shanghai Pulmonary Hospital, this platform is designed to overcome primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). In the tumor microenvironment, the E3 ubiquitin ligase HUWE1 mediates the ubiquitination-dependent degradation of YES1, a tyrosine-protein kinase critical for NK cell metabolic homeostasis, cytoskeletal organization, and effector function. This degradation is further enhanced in immunosuppressive niches rich in SPP1 (osteopontin). By incorporating YES1 stabilization, these engineered CAR-NK cells resist ubiquitin-mediated degradation, restoring NK cell persistence and cytotoxicity under immunosuppressive conditions.
- Other names
- YES1-stabilized CAR-NK cellsYES-1-stabilized CAR-NK cellsYES 1-stabilized CAR-NK cells
02
Targets
HUWE1SPP1 (Osteopontin)YES1 (YES proto-oncogene 1 tyrosine kinase)
Beyond the preview
Go deeper on YES1-stabilized CAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YES1-stabilized CAR-NK.